MétaCan
Menu
Back to cohort
Record W2127924807

Utilisation de l’aprépitant pour les nausées et les vomissements réfractaires secondaires à la chimiothérapie chez une adolescente

2005· article· fr· W2127924807 on OpenAlexaboutno aff
Geneviève Ouellet, Roxane Therrien

Bibliographic record

Venuenot available
Typearticle
Languagefr
FieldMedicine
TopicNausea and vomiting management
Canadian institutionsnot available
Fundersnot available
KeywordsAprepitantMedicineGynecologyAntiemeticVomitingInternal medicine
DOInot available

Abstract

fetched live from OpenAlex

Resume Objectif : Presenter un cas d’utilisation de l’aprepitant. Resume du cas : Il s’agit d’une patiente de 15 ans atteinte d’un osteosarcome et traitee par chimiotherapie hautement emetisante a base de cisplatine. La patiente a eprouve, lors de ses premiers cycles de traitement, des nausees et des vomissements aigus et retardes tres importants, refractaires aux antiemetiques habituels. Un essai a l’aprepitant a ete tente. Ce medicament n’etant pas commercialise au Canada, il a du etre obtenu par le biais du Programme d’acces special aux medicaments (PAS) de Sante Canada. L’aprepitant a ameliore de facon significative le controle des nausees et des vomissements chez cette patiente. Discussion : L’aprepitant est un antagoniste des recepteurs de la neurokinine-1 (NK-1). Il est administre par voie orale en combinaison avec les antinauseeux conventionnels, incluant les antagonistes des recepteurs 5-HT3. Plusieurs regimes ont ete testes post-cisplatine, demontrant tous une meilleure efficacite dans la prevention des nausees et des vomissements aigus et retardes, comparativement a la therapie standard seule. Conclusion : L’aprepitant est un antiemetique qui semble prometteur, particulierement dans le traitement des nausees et des vomissements retardes. Toutefois, certaines questions doivent encore etre elucidees par des etudes cliniques, surtout chez les enfants et les adolescents. Abstract Objective: To report the use of aprepitant in a case. Case Summary: A 15 year old patient with osteosarcoma was treated with highly emetogenic cisplatinbased chemotherapy. The patient suffered severe acute and delayed nausea and vomiting, which were refractory to standard anti-emetic medication. Aprepitant was administered in this patient. Since this medication is not commercially available in Canada, it was obtained through the Health Canada Special Access Programme. Aprepitant significantly improved the control of nausea and vomiting in this patient. Discussion: Aprepitant is a neurokinin-1 receptor antagonist (NK1). It is administered orally in combination with standard anti-emetics, including the 5-HT3 receptor antagonists. Many schedules have been evaluated post-cisplatin administration and improved efficacy in the prevention of acute and delayed nausea and vomiting has been demonstrated, as compared to standard therapy. Conclusion: Aprepitant is a promising anti-emetic, particularly in the treatment of delayed nausea and vomiting. Nonetheless, many questions remain to be answered with further clinical trials, especially in children and adolescents. Key Words: aprepitant, anti-emetics, substance P, NK-1 receptor antagonists, cisplatin

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.540
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.306
Teacher spread0.283 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2005
Admission routes1
Has abstractyes

Explore more

Same topicNausea and vomiting managementFrench-language works237,207